Latest DURECT Corporation Stories
CUPERTINO, Calif., Nov. 3, 2010 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2010. Total revenues were $8.1 million for the three months ended September 30, 2010 compared to $8.4 million for the three months ended September 30, 2009; revenues in the 2009 period included $3.0 million recognized from the sale of certain excipients used in REMOXY® to King Pharmaceuticals in prior periods. Net loss for...
CUPERTINO, Calif., Nov. 2, 2010 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has been awarded grants totaling $733,438 to advance our programs in post-operative pain relief, attention deficit disorder (ADHD) and chronic diseases treated with biologic agents. The grants are being awarded under the Patient Protection and Affordable Care Act of 2010. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo:...
CUPERTINO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, November 3, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast of the...
CUPERTINO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended June 30, 2010. Total revenues were $7.3 million for the three months ended June 30, 2010 compared to $4.9 million for the three months ended June 30, 2009. Net loss for the three months ended June 30, 2010 was $6.3 million, compared to a net loss of $7.5 million for the same period in 2009. (Logo:...
CUPERTINO, Calif., July 29 /PRNewswire-FirstCall/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) second quarter 2010 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, August 4, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast of the...
CUPERTINO, Calif., July 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matthew J. Hogan, Chief Financial Officer, will be presenting at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5 at 1:45 p.m. Eastern Time. The conference is being held at the Sheraton New York Hotel. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live audio webcast...
CUPERTINO, Calif., July 1 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it has secured a committed equity financing facility under which it may sell up to $50 million of its registered common stock to Azimuth Opportunity Ltd. for a term of 24 months. DURECT is not obligated to utilize any of the $50 million facility. DURECT did not pay a commitment fee or issue any warrants to secure this facility. (Logo:...
CUPERTINO, Calif., June 16 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today results from a European Phase IIb hysterectomy clinical trial conducted by Nycomed of POSIDUR(TM) (also known as SABER(TM)-bupivacaine or Optesia(TM) in the E.U.), a proprietary product under development for the treatment of post-surgical pain. (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) This hysterectomy trial...
CUPERTINO, Calif., June 7 /PRNewswire-FirstCall/ -- In conjunction with the announcement of a POSIDUR(TM) (SABER(TM)-Bupivacaine) collaboration between DURECT Corporation (Nasdaq: DRRX) and Hospira, Inc. (NYSE: HSP), you are invited to listen to a conference call that will be broadcast live over the internet on Monday, June 7, 2010 at 5:00 pm Eastern Time (2:00 pm Pacific Time). (Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO) A live audio webcast of the presentation will be...
LAKE FOREST, Ill. , and CUPERTINO, Calif., June 7 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, and DURECT Corporation, a specialty pharmaceutical company (Nasdaq: DRRX), today announced that the companies have entered into a licensing agreement to develop and market DURECT's POSIDUR(TM) (SABER(TM)-bupivacaine) a long-acting version of the anesthetic bupivacaine currently in Phase III clinical trials. Hospira will...
